Company Filing History:
Years Active: 2025
Title: Takao Mandai: Innovator in Cholinergic Modulation
Introduction
Takao Mandai is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmacology, particularly in the development of methods for treating Alzheimer's disease. His innovative approach focuses on reducing cholinergic side effects associated with muscarinic M1 receptor positive allosteric modulators.
Latest Patents
Takao Mandai holds 1 patent for his invention titled "Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators." This patent presents a useful and efficient screening method for identifying cholinergic muscarinic M1 receptor positive allosteric modulators (M1PAM) that minimize cholinergic side effects. The invention also outlines methods for treating Alzheimer's disease and reducing cholinergic side effects using M1PAM selected through the screening method.
Career Highlights
Mandai is associated with Takeda Pharmaceutical Company Limited, where he has been instrumental in advancing research related to cholinergic modulation. His work has contributed to the understanding of M1PAM and its potential therapeutic applications.
Collaborations
Some of his notable coworkers include Haruhide Kimura and Yuu Sako, who have collaborated with him on various research projects.
Conclusion
Takao Mandai's innovative work in the field of pharmacology highlights the importance of developing effective treatments for Alzheimer's disease while minimizing side effects. His contributions continue to influence research and development in this critical area of medicine.